A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population-PREDICTORS 4

We found similar sensitivity for CIN3+ in PreservCyt and SurePath for 5 nucleic acid tests in the two media in a referral population, but signal strength and positivity rates were lower in SurePath except for the Onclarity test. These results need to be replicated in a screening population.